Lymphoma Research Study
|
Alemtuzumab (Campath) for T-LGL Lymphoproliferative Disorders
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders. The study drug, a monoclonal antibody, may help increase blood counts and reduce the number of abnormal T cell large granular lymphocytes. If eligible to participate, consenting subjects will receive an intravenous infusion of study medication alemtuzumab (Campath) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with T-LGL and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Lymphoma Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Lymphoma
|
If you or someone you know is diagnosed with Non- Hodgkin's lymphoma or Mantle cell lymphoma, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant to Treat Lymphoma
|
If you or someone you know is diagnosed with Non- Hodgkin's lymphoma or Mantle Cell lymphoma, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant and T-Cell Add Back to Treat Lymphoma
|
If you (or someone you know) have been diagnosed with Non- Hodgkin's lymphoma or Mantle cell lymphoma, you may be able to participate in our clinical trial designed to decrease graft-versus- host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant. Specifically, we are testing whether special treatment of your donor's transplant cells and delaying the transfusion of donor lymphocytes (immune cells) will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister donor to participate in this trial.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant for High Risk Patients with Lymphoma
|
If you have been diagnosed with Non-Hodgkin's lymphoma or Hodgkin's Disease you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft- versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute